JP2020514282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514282A5 JP2020514282A5 JP2019534858A JP2019534858A JP2020514282A5 JP 2020514282 A5 JP2020514282 A5 JP 2020514282A5 JP 2019534858 A JP2019534858 A JP 2019534858A JP 2019534858 A JP2019534858 A JP 2019534858A JP 2020514282 A5 JP2020514282 A5 JP 2020514282A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cbd
- thc
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 15
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 10
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 10
- 229950011318 cannabidiol Drugs 0.000 claims 10
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 10
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 10
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 7
- 229960004242 dronabinol Drugs 0.000 claims 6
- 206010015037 epilepsy Diseases 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000008697 Cannabis sativa Nutrition 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008169 grapeseed oil Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022165695A JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436861P | 2016-12-20 | 2016-12-20 | |
| US62/436,861 | 2016-12-20 | ||
| PCT/IB2017/001683 WO2018115962A1 (en) | 2016-12-20 | 2017-12-20 | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165695A Division JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514282A JP2020514282A (ja) | 2020-05-21 |
| JP2020514282A5 true JP2020514282A5 (enExample) | 2021-02-04 |
Family
ID=61028091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534858A Pending JP2020514282A (ja) | 2016-12-20 | 2017-12-20 | 新規カンナビノイド組成物および使用方法 |
| JP2022165695A Pending JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165695A Pending JP2023001138A (ja) | 2016-12-20 | 2022-10-14 | 新規カンナビノイド組成物および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200215022A1 (enExample) |
| EP (1) | EP3558297A1 (enExample) |
| JP (2) | JP2020514282A (enExample) |
| KR (1) | KR20190099221A (enExample) |
| AU (1) | AU2017381587A1 (enExample) |
| BR (1) | BR112019012776A2 (enExample) |
| CA (1) | CA3046320A1 (enExample) |
| CL (1) | CL2019001668A1 (enExample) |
| CO (1) | CO2019006911A2 (enExample) |
| MX (1) | MX2019007496A (enExample) |
| PE (1) | PE20200338A1 (enExample) |
| WO (1) | WO2018115962A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| IL261132A (en) * | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| GB2580653A (en) * | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
| EP3931330A4 (en) | 2019-02-25 | 2023-03-15 | Ginkgo Bioworks, Inc. | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS |
| US11759447B1 (en) | 2019-06-26 | 2023-09-19 | RCR BioPharma | Compound and method for treating diseases and disorders |
| GB2598922A (en) | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023047308A1 (en) * | 2021-09-22 | 2023-03-30 | Avicanna Inc. | Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy |
| WO2023200906A1 (en) | 2022-04-12 | 2023-10-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03007215A (es) * | 2001-02-14 | 2003-12-04 | Gw Pharma Ltd | Formulaciones farmaceuticas. |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| BR112017012434A2 (pt) * | 2014-12-12 | 2018-02-20 | Ojai Energetics Pbc | composições de canabinóide microencapsuladas |
| CN107530318A (zh) * | 2015-03-02 | 2018-01-02 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| NZ735216A (en) * | 2016-02-11 | 2019-08-30 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
-
2017
- 2017-12-20 AU AU2017381587A patent/AU2017381587A1/en not_active Abandoned
- 2017-12-20 CA CA3046320A patent/CA3046320A1/en active Pending
- 2017-12-20 PE PE2019001299A patent/PE20200338A1/es unknown
- 2017-12-20 EP EP17835701.8A patent/EP3558297A1/en not_active Withdrawn
- 2017-12-20 KR KR1020197018587A patent/KR20190099221A/ko not_active Ceased
- 2017-12-20 JP JP2019534858A patent/JP2020514282A/ja active Pending
- 2017-12-20 BR BR112019012776A patent/BR112019012776A2/pt not_active IP Right Cessation
- 2017-12-20 WO PCT/IB2017/001683 patent/WO2018115962A1/en not_active Ceased
- 2017-12-20 US US16/471,407 patent/US20200215022A1/en not_active Abandoned
- 2017-12-20 MX MX2019007496A patent/MX2019007496A/es unknown
-
2019
- 2019-06-17 CL CL2019001668A patent/CL2019001668A1/es unknown
- 2019-06-27 CO CONC2019/0006911A patent/CO2019006911A2/es unknown
-
2022
- 2022-10-14 JP JP2022165695A patent/JP2023001138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514282A5 (enExample) | ||
| JP2023168448A5 (enExample) | ||
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| JP2022180461A5 (enExample) | ||
| FI3883563T3 (fi) | Kannabidiolityyppinen kannabinoidiyhdiste | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2020524151A5 (enExample) | ||
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| JP2014528474A5 (enExample) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2016523862A5 (enExample) | ||
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| JP2016517888A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2018513188A5 (enExample) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| JPWO2021099783A5 (enExample) | ||
| JPWO2021099781A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP5841903B2 (ja) | 肝障害の治療または肝機能の向上のための薬剤 | |
| RU2011129815A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JP2015524460A5 (enExample) | ||
| CN110559287A (zh) | 一种用于治疗癌症的药物组合物及其应用 |